Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas

被引:33
|
作者
Hart, Terance [1 ]
Macias, Alba T. [1 ]
Benwell, Karen [1 ]
Brooks, Teresa [1 ]
D'Alessandro, Jalanie [1 ]
Dokurno, Pawel [1 ]
Francis, Geraint [1 ]
Gibbons, Ben [2 ]
Haymes, Timothy [2 ]
Kennett, Guy [2 ]
Lightowler, Sean [2 ]
Mansell, Howard [2 ]
Matassova, Natalia [1 ]
Misra, Anil [2 ]
Padfield, Anthony [2 ]
Parsons, Rachel [1 ]
Pratt, Robert [2 ]
Robertson, Alan [1 ]
Walls, Steven [1 ]
Wong, Melanie [1 ]
Roughley, Stephen [1 ]
机构
[1] Vernalis R&D Ltd, Cambridge CB21 6GB, England
[2] Vernalis R&D Ltd, Winnersh RG41 5UA, England
关键词
FAAH; fatty acid amide hydrolase; Azetidine; Urea; Inhibitor; ENZYME;
D O I
10.1016/j.bmcl.2009.05.097
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report the discovery of a novel, chiral azetidine urea inhibitor of Fatty Acid Amide Hydrolase ( FAAH,) and describe the surprising species selectivity of VER-156084 versus rat and human FAAH and also hCB1. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4241 / 4244
页数:4
相关论文
共 50 条
  • [31] Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase
    Keith, John M.
    Jones, William M.
    Pierce, Joan M.
    Seierstad, Mark
    Palmer, James A.
    Webb, Michael
    Karbarz, Mark J.
    Scott, Brian P.
    Wilson, Sandy J.
    Luo, Lin
    Wennerholm, Michelle L.
    Chang, Leon
    Brown, Sean M.
    Rizzolio, Michele
    Rynberg, Raymond
    Chaplan, Sandra R.
    Breitenbucher, J. Guy
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (03) : 737 - 741
  • [32] Developing novel fatty acid amide hydrolase inhibitors for the treatment of pain
    Faloon, Jordan
    Ezzili, Cyrine
    Giuvelis, Denise
    Lowery, John J.
    McGlinchey, Nicholas
    Boger, Dale
    Bilsky, Edward J.
    FASEB JOURNAL, 2011, 25
  • [33] Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase
    Garfunkle, Joie
    Ezzili, Cyrine
    Rayl, Thomas J.
    Hochstatter, Dustin G.
    Hwang, Inkyu
    Boger, Dale L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (15) : 4392 - 4403
  • [34] Discovery of Uracil Derivatives as Potent Inhibitors of Fatty Acid Amide Hydrolase
    Qiu, Yan
    Zhang, Yang
    Li, Yuhang
    Ren, Jie
    MOLECULES, 2016, 21 (02)
  • [35] Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors
    Gustin, Darin J.
    Ma, Zhihua
    Min, Xiaoshan
    Li, Yihong
    Hedberg, Christine
    Guimaraes, Cris
    Porter, Amy C.
    Lindstrom, Michelle
    Lester-Zeiner, Dianna
    Xu, Guifen
    Carlson, Timothy J.
    Xiao, Shouhua
    Meleza, Cesar
    Connors, Richard
    Wang, Zhulun
    Kayser, Frank
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) : 2492 - 2496
  • [36] (Indolylalkyl) piperidine carbamates as inhibitors of fatty acid amide hydrolase (FAAH)
    Dahlhaus, Helmut
    Hanekamp, Walburga
    Lehr, Matthias
    MEDCHEMCOMM, 2017, 8 (03) : 616 - 620
  • [37] Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH)
    Timmons, Amy
    Seierstad, Mark
    Apodaca, Rich
    Epperson, Matt
    Pippel, Dan
    Brown, Sean
    Chang, Leon
    Scott, Brian
    Webb, Michael
    Chaplan, Sandra R.
    Breitenbucher, J. Guy
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 2109 - 2113
  • [38] α-Ketoheterocycle-Based Inhibitors of Fatty Acid Amide Hydrolase (FAAH)
    Otrubova, Katerina
    Boger, Dale L.
    ACS CHEMICAL NEUROSCIENCE, 2012, 3 (05): : 340 - 348
  • [39] Development of Dual Inhibitors of Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase with Tetrazole Core
    Mehrandish, Sara
    Rezaee, Elham
    Sedaghat, Anna
    Heidarli, Elmira
    Naderi, Nima
    Tabatabai, Sayyed Abbas
    MEDICINAL CHEMISTRY, 2023, 19 (10) : 1037 - 1048
  • [40] Design and Synthesis of Dual Inhibitors Targeting Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase
    Rodriguez-Villafane, Adriana
    Pecic, Stevan
    Kandasamy, Ram
    Hammock, Bruce
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (03):